2026 Analytical R&D LNP Characterization (PhD) jobs in United States
cer-icon
Apply on Employer Site
company-logo

AbbVie · 1 day ago

2026 Analytical R&D LNP Characterization (PhD)

AbbVie is a pharmaceutical company dedicated to discovering and delivering innovative medicines. They are seeking a highly motivated intern to drive innovation within analytical sciences, specifically focusing on mRNA-LNP characterization and the evaluation of multi-attribute instruments.

BiotechnologyFinancial ServicesHealth CareMedicalPharmaceuticalVenture Capital
check
Comp. & Benefits
check
H1B Sponsor Likelynote

Responsibilities

Develop methods such as DLS, MALS, Encapsulation, HPLC, to support the optimal LNP formulation
Evaluate the capabilities of a multi-attribute (MA) instrument to integrate with current analytical methodologies
Author SOP and update periodically at cross-functional meetings

Qualification

PhD in analytical chemistryDLSMALSHPLCLNP characterizationMethod developmentSOP authoring

Required

Currently enrolled in university, pursuing a PhD in analytical chemistry or other related fields
Must be enrolled in university for at least one semester following the internship

Preferred

Expected graduation date between December 2026 – June 2027
Hands on experience in basic analytical methods to characterize LNP
Experience working with DLS, MALS, Encapsulation, HPLC

Benefits

Competitive pay
Relocation support for eligible students
Select wellness benefits and paid holiday / sick time

Company

AbbVie is a biopharmaceutical company focused on immunology, oncology, neuroscience, virology, and aesthetics. It is a sub-organization of AbbVie.

H1B Sponsorship

AbbVie has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (273)
2024 (190)
2023 (225)
2022 (284)
2021 (186)
2020 (186)

Funding

Current Stage
Public Company
Total Funding
$15B
2024-02-27Post Ipo Debt· $15B
2023-03-08Post Ipo Equity· $0.25M
2012-12-20IPO

Leadership Team

leader-logo
Robert Michael
Chairman of the Board and Chief Executive Officer
linkedin
leader-logo
Micah Bregman
Vice President, Global Strategy and Pipeline, Allergan Aesthetics
linkedin
Company data provided by crunchbase